MedPath

Bioequivalence study of Metformin 1000 mg E.R. Tablet in 24 healthy male under fasting conditions

Not Applicable
Conditions
Diabetes mellitus.
Diabetes mellitus due to underlying condition
Registration Number
IRCT20180620040164N67
Lead Sponsor
Dorsa Pharmaceutical Co.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Male
Target Recruitment
24
Inclusion Criteria

Healthy subjects (male) between 18 – 45 years of age and Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18.5 and 30 (inclusive), calculated as kg/m2.
Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.

Exclusion Criteria

History of known sensitivity to the tested products
Associated acute or chronic infections
Blood pressure in standing position and after 5 minutes of rest, systole less than 90 or more than 140 mm Hg and diastole less than 50 or more than 90 mm Hg.
Heart rate less than 50 or more than 90 beats per minute
Abnormalities in ECG include (PR > 210 msec, QRS complex > 120 msec, QTcF > 430 msec)
Smoking more than 10 cigarettes a day
Loss of more than 500 ml of blood in less than 7 days.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath